

## Oregon Health Plan (OHP) prescribers – Changes to fee-for-service coverage of provider-administered biologic drugs for severe asthma

### Prior authorization requirements effective January 1, 2022

Starting January 1, 2022, the Oregon Health Authority (OHA) will require prior authorization (PA) for biologic agents administered to treat severe asthma. OHA will deny fee-for-service claims that do not have an approved PA on file.

Generic Name	Brand Name
benralizumab	FASENRA®
dupilumab	DUPIXENT®
mepolizumab	NUCALA®
omalizumab	XOLAIR®
reslizumab	CINQAIR®

This change applies to all biologic agents listed in the table (as well as any new FDA-approved drugs in this class), when administered by a provider:

- For all indications (including both asthma and non-asthma indications), **and**
- For either subcutaneous or intravenous administration.

OHA will use the same PA criteria that already applies to pharmaceutical (patient-administered) biologic agents for this class, posted at [www.orpd.org/drugs](http://www.orpd.org/drugs) under “Asthma Biologics.”

- Administration must be for FDA-approved indications and OHP-funded diagnoses.
- Confirmation of patient access to epinephrine for management of delayed anaphylaxis is required.
- If the request is for management of atopic dermatitis, asthma, or nasal polyps, the drug should be administered by or in consultation with an appropriate specialist.
- Depending on the requested agent and indication, requests may also require documentation of disease severity, details on the trial and failure of one or more conventional therapies, and adherence to current therapy.
- Continued authorization requires documented patient improvement.

### What should you do?

Please review the following list of patients who have had recent claims for provider-administered biologics.

For any patients needing continued therapy for these agents:

- Please request PA prior to their next scheduled dose.
- Send all required information, including all relevant ICD-10 diagnosis codes for primary and comorbid conditions, and history of use of other agents (both biologic and non-biologic) for the conditions.

You can submit PA requests three ways:

1. Call the Oregon Pharmacy Call Center at 888-202-2126;
2. Submit via the secure Provider Web Portal at <https://www.or-medicaid.gov>; or
3. Fax 888-346-0178. Use the form at <https://sharedsystems.dhsoha.state.or.us/DHSForms/Served/he3978.pdf>

### Questions?

- **About PA for fee-for-service prescriptions:** Call the Oregon Pharmacy Call Center at 888-202-2126.
- **About using the Provider Web Portal:** Contact the Provider Services Unit at [dmap.providerservices@dhsoha.state.or.us](mailto:dmap.providerservices@dhsoha.state.or.us) or call 800-336-6016.
- **About physical health prescriptions for patients in a coordinated care organization (CCO):** Contact the CCO.

**TO:** <Prescriber name>  
<Street Address, City OR Zip>  
<Oregon Medicaid ID>

Telephone: <xxx-xxx-xxxx>  
Fax: <xxx-xxx-xxxx>

**FROM:** Oregon Pharmacy Call Center

Telephone: 888-202-2126  
Fax: 888-346-0178

**SUBJECT: Patients with recent claims for physician-administered biologics for severe asthma –  
Please review and take action**

**Confidentiality Notice:**

The information contained in this request is confidential and legally privileged. It is intended only for use of the recipient(s) named. If you are not the intended recipient, you are hereby notified that the disclosure, copying, distribution, or taking of any action in regards to the contents of this fax document- except its direct delivery to the intended recipient – is strictly prohibited. If you have received this request in error, please notify the sender immediately and destroy all copies of this request along with its contents and delete from your system, if applicable.

The Oregon Health Authority (OHA) has reviewed recent fee-for-service (FFS) claims data linked to your National Provider Identifier for affected physician-administered biologic agents. This review resulted in the following list of patients.

In order for OHA to process future FFS claims for these agents:

- Request prior authorization (PA) from OHA before the patient’s next scheduled dose.
- Follow the PA criteria at [www.orpdl.org/drugs](http://www.orpdl.org/drugs) under “Asthma Biologics.”

<b>Patient</b>	<b>Date of Birth</b>	<b>Medicaid Member ID</b>	<b>Drug</b>	<b>Date of most recent billed claim</b>
Jane Doe	xx/xx/xxxx	xxxxxxxx	generic drug name	xx/xx/xxxx
Joe Johnson	xx/xx/xxxx	xxxxxxxx	benralizumab	xx/xx/xxxx
John Smith	xx/xx/xxxx	xxxxxxxx	mepolizumab	xx/xx/xxxx
...				
...				